Randomized Multicenter(隨機多中心)到底是什麼？
Randomized Multicenter 隨機多中心 - These findings suggest that a randomized multicentered controlled study comparing rapid vs. [1] Whether inflammation can modulate Lp(a)-associated cardiovascular (CV) risk during secondary prevention is unknown ACCELERATE was a randomized multicenter. [2]這些發現表明，一項隨機多中心對照研究比較了快速與 [1] 炎症是否可以調節二級預防期間與 Lp(a) 相關的心血管 (CV) 風險尚不清楚 ACCELERATE 是一項隨機多中心研究。 [2]
Prospective Randomized Multicenter 前瞻性隨機多中心
This time, we conducted this study to compare the efficacies and complication rates of uncovered MS and covered MS in unresectable malignant distal biliary obstructions at a prospective randomized multicenter trial. [1] Methods This post-hoc analysis from a prospective randomized multicenter trial included 225 patients with a 48-week follow-up period. [2] Larger, prospective randomized multicenter studies are needed in order to confirm these findings. [3] A prospective randomized multicenter study (Envision) demonstrated the clinical efficacy of monthly subcutaneous injection of Givosiran for the prevention of attacks of acute hepatic porphyria (AHP). [4] Methods The DAT computer program was developed with a group of 46 post thyroidectomy patients, and then applied in a prospective randomized multicenter validation trial in 145 unselected patients admitted for total thyroidectomy for goiter, differentiated thyroid cancer or thyrotoxicosis. [5] Clinical impact: Pending a larger prospective randomized multicenter comparison between in-bore and fusion biopsy, in-bore may be the preferred approach should performing only biopsy of a suspicious target, without concurrent systematic biopsy, be considered clinically appropriate. [6] Materials and Methods: Nationwide prospective randomized multicenter study involving 43 centers throughout France allowing for the inclusion of >70% of all French cardiology residents. [7] Interestingly, a well-designed prospective randomized multicenter study (PIONEER-HF) showed an improved clinical outcome and stress/injury biomarker profile after in-hospital administration of sacubitril/valsartan (sac/val) as compared to enalapril, in hemodynamically stable patients with AHF. [8] STUDY DESIGN Post-hoc analysis of 5-year follow-up data from a prospective randomized multicenter trial. [9] Two prospective randomized multicenter studies (PIONEER-HF and TRANSITION) in patients hospitalized for acute heart failure (AHF) have shown an improved clinical outcome and biomarker profile as compared to enalapril, and good tolerability, safety and feasibility of initiating in-hospital administration of S/V. [10] Large prospective randomized multicenter trials are needed to refine the cut-off values and algorithms and validate the clinical usefulness of these biomarkers. [11] BACKGROUND To our knowledge, there is an absence of prospective randomized multicenter controlled trials evaluating both the impact of technique and mesh type on outcomes in complicated ventral hernia repair. [12] Methods A prospective randomized multicenter study was performed. [13] METHODS Patients with inoperable high-grade MHSs were enrolled in this prospective randomized multicenter study. [14] The prospective randomized multicenter Freeway study evaluated the possible hemodynamic and clinical benefits of primary stent insertion followed by percutaneous transluminal angioplasty (PTA) with drug-eluting balloons (DEB) over post-stent insertion PTA with standard balloons in the treatment of symptomatic femoropopliteal arteriosclerotic lesions. [15] Methods In a prospective randomized multicenter clinical trial, patients with solid pancreatic lesions underwent EUS-FNB with either a 20-gauge or a 25-gauge FNB needle. [16] Background This study aimed to compare the functional and clinical outcomes between the deltoid split (DS) approach and the classic deltopectoral (DP) approach for locking plate fixation of proximal humerus fractures (PHF) in a prospective randomized multicenter study. [17] However, further long-term prospective randomized multicenter trials involving comparative studies are necessary to confirm these findings. [18] This prospective randomized multicenter trial comparing in utero fetal MMC (fMMC) closure to routine postnatal closure demonstrated a decreased need for shunting, reversal of hindbrain herniation, and improved neurologic function in the prenatal repair group, although maternal complications and prematurity were more frequently encountered. [19] DESIGN This prospective randomized multicenter study determined whole-body and liver protein synthesis, splanchnic protein metabolism and appendicular skeletal muscle mass (ASMM) in 24 malnourished older patients [80-92 years; 18 women and 6 men] in inpatient rehabilitation units. [20] The benefit of in-utero closure was debated until the results of the prospective randomized multicenter Management of Myelomeningocele Study (MOMS trial) were published, demonstrating a decreased need for shunting, reversal of hindbrain herniation, and better neurologic function in the prenatal repair group compared to postnatal repair. [21]這一次，我們進行了這項研究，以在一項前瞻性隨機多中心試驗中比較未覆蓋 MS 和覆蓋 MS 在不可切除的惡性遠端膽道梗阻中的療效和並發症發生率。 [1] 方法 這項來自前瞻性隨機多中心試驗的事後分析包括 225 名患者，隨訪期為 48 週。 [2] 需要更大規模的前瞻性隨機多中心研究來證實這些發現。 [3] 一項前瞻性隨機多中心研究 (Envision) 證明了每月皮下注射 Givosiran 對預防急性肝卟啉症 (AHP) 發作的臨床療效。 [4] 方法 DAT 計算機程序由一組 46 名甲狀腺切除術後患者開發，然後應用於一項前瞻性隨機多中心驗證試驗，該試驗對 145 名因甲狀腺腫、分化型甲狀腺癌或甲狀腺毒症而入院接受全甲狀腺切除術的未選擇患者進行了前瞻性隨機多中心驗證試驗。 [5] 臨床影響：在孔內活檢和融合活檢之間進行更大規模的前瞻性隨機多中心比較之前，孔內可能是首選方法，應認為僅對可疑目標進行活檢，而不進行同時進行的系統活檢，被認為是臨床上合適的。 [6] 材料和方法：全國性前瞻性隨機多中心研究，涉及全法國 43 個中心，納入了超過 70% 的法國心髒病學住院醫師。 [7] 有趣的是，一項精心設計的前瞻性隨機多中心研究 (PIONEER-HF) 顯示，與依那普利相比，在院內給予沙庫巴曲/纈沙坦 (sac/val) 後，在血流動力學穩定的患有心力衰竭。 [8] 學習規劃 一項前瞻性隨機多中心試驗的 5 年隨訪數據的事後分析。 [9] 兩項針對急性心力衰竭 (AHF) 住院患者的前瞻性隨機多中心研究（PIONEER-HF 和 TRANSITION）顯示，與依那普利相比，臨床結果和生物標誌物譜有所改善，並且在院內開始使用本品具有良好的耐受性、安全性和可行性。 S/V。 [10] 需要大型前瞻性隨機多中心試驗來完善臨界值和算法，並驗證這些生物標誌物的臨床實用性。 [11] 背景 據我們所知，目前尚無前瞻性隨機多中心對照試驗評估技術和補片類型對複雜腹疝修復結果的影響。 [12] 方法進行前瞻性隨機多中心研究。 [13] 方法 這項前瞻性隨機多中心研究招募了不能手術的高級 MHS 患者。 [14] 前瞻性隨機多中心 Freeway 研究評估了在治療症狀性股膕動脈硬化病變中，初次支架置入繼以經皮腔內血管成形術 (PTA) 與藥物洗脫球囊 (DEB) 相比支架置入後 PTA 與標準球囊可能的血流動力學和臨床益處. [15] 方法 在一項前瞻性隨機多中心臨床試驗中，胰腺實性病變患者使用 20 號或 25 號 FNB 針進行 EUS-FNB。 [16] 背景 本研究旨在在一項前瞻性隨機多中心研究中比較三角肌劈開 (DS) 入路與經典三角胸肌 (DP) 入路鎖定鋼板固定肱骨近端骨折 (PHF) 的功能和臨床結果。 [17] 然而，需要進一步的涉及比較研究的長期前瞻性隨機多中心試驗來證實這些發現。 [18] 這項前瞻性隨機多中心試驗比較了子宮內胎兒 MMC (fMMC) 閉合與常規產後閉合的比較，表明產前修復組的分流需求減少、後腦疝逆轉和神經功能改善，儘管母體並發症和早產的發生率更高。 [19] nan [20] nan [21]
Large Randomized Multicenter 大型隨機多中心
In case the results indicate that cognitive performance can be improved with CR, and whether or not tDCS will lead to additional improvement, this pilot trial will be extended to a large randomized multicenter study. [1] It should be pointed out that the scientific literature is to some extent controversial due to a paucity of large randomized multicenter studies with long-term follow-up. [2] Large randomized multicenter clinical trials are needed to discern the exact therapeutic potentials of MSC in COVID-19-induced ARDS. [3] To date, there is a lack of robust published data regarding the safety and effectiveness of various therapies, and there continues to be a need for large randomized multicenter trials comparing newer therapies to treat this refractory condition. [4] Further large randomized multicenter studies are required to find influence of obesity in relation to ethnicity and other factors to ovarian reserve function. [5] A large randomized multicenter study highlighted doxycycline as a feasible alternative to systemic corticosteroids in patients not suitable for long-term steroid use. [6]如果結果表明 CR 可以改善認知能力，以及 tDCS 是否會帶來額外的改善，該試點試驗將擴展到一項大型隨機多中心研究。 [1] 應該指出的是，由於缺乏長期隨訪的大型隨機多中心研究，科學文獻在一定程度上存在爭議。 [2] 需要大型隨機多中心臨床試驗來辨別 MSC 在 COVID-19 誘導的 ARDS 中的確切治療潛力。 [3] 迄今為止，缺乏關於各種療法的安全性和有效性的可靠已發表數據，並且仍然需要大型隨機多中心試驗來比較治療這種難治性疾病的新療法。 [4] 需要進一步的大型隨機多中心研究來發現肥胖與種族和其他因素對卵巢儲備功能的影響。 [5] 一項大型隨機多中心研究強調，對於不適合長期使用類固醇的患者，強力黴素是全身性皮質類固醇的可行替代品。 [6]
Scale Randomized Multicenter 規模隨機多中心
There is a need for a large-scale randomized multicenter prospective study to verify the advantages of minimally invasive approaches in the management of symptomatic supratentorial intracerebral hemorrhages. [1] Five large scale randomized multicenter phase III trials have been conducted to evaluate the efficacy of liraglutide as a weight loss agent. [2] Early phase I and II studies have shown the benefits of PRRT, but it was the NETTER-1 trial (a large-scale randomized multicenter trial for progressive well-differentiated advanced or metastatic somatostatin receptor-positive midgut carcinoid tumors) that provided high-level evidence of improved overall response rate, and progression-free survival compared with long-acting octreotide. [3]需要一項大規模隨機多中心前瞻性研究來驗證微創方法在治療症狀性幕上腦出血中的優勢。 [1] 已經進行了五項大規模隨機多中心 III 期試驗，以評估利拉魯肽作為減肥藥的功效。 [2] 早期 I 期和 II 期研究顯示了 PRRT 的益處，但 NETTER-1 試驗（一項針對進行性高分化晚期或轉移性生長抑素受體陽性中腸類癌的大規模隨機多中心試驗）提供了高水平與長效奧曲肽相比，總體緩解率和無進展生存期得到改善的證據。 [3]
Week Randomized Multicenter
This 12-week randomized multicenter trial evaluated efficacy and safety of TNX-102 SL, a bedtime sublingual formulation of cyclobenzaprine, in patients with military-related PTSD randomized to TNX-102 SL 2. [1] In a pre‐specified subgroup analysis of a 12‐week randomized multicenter study, we investigated effects of valsartan/amlodipine 80/5 mg single‐pill combination (n = 75) and nifedipine GITS 30 mg (n = 75) on ambulatory blood pressure (BP) and arterial stiffness assessed by brachial‐ankle pulse wave velocity (PWV) in patients with uncontrolled hypertension. [2]這項為期 12 週的隨機多中心試驗評估了 TNX-102 SL（一種環苯扎林的睡前舌下製劑）在隨機分配至 TNX-102 SL 2 的軍事相關 PTSD 患者中的療效和安全性。 [1] 在一項為期 12 週的隨機多中心研究的預先指定的亞組分析中，我們調查了纈沙坦/氨氯地平 80/5 mg 單丸組合 (n = 75) 和硝苯地平 GITS 30 mg (n = 75) 對動態血壓的影響通過臂踝脈搏波速度 (PWV) 評估未控制的高血壓患者的 (BP) 和動脈僵硬度。 [2]
Blind Randomized Multicenter
Methods: This is a double-blind randomized multicenter study in 36 centers in the U. [1] [1] report the results of a double-blind randomized multicenter international study comparing rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with the biosimilar RTXM83 in combination with CHOP chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). [2]方法：這是一項在美國 36 個中心進行的雙盲隨機多中心研究。 [1] [1] 報告了一項雙盲隨機多中心國際研究的結果，該研究比較了利妥昔單抗聯合環磷酰胺、多柔比星、長春新鹼和潑尼松 (CHOP) 與生物仿製藥 RTXM83 聯合 CHOP 化療對新診斷的瀰漫性大 B 細胞患者的療效淋巴瘤（DLBCL）。 [2]
Designed Randomized Multicenter
Moreover, data on long-term efficacy and safety coming from well-designed randomized multicenter controlled trials are still needed to bring EUS-guided procedures to the next level. [1] Therefore, there is a need for a well-designed randomized multicenter clinical trial to evaluate the optimal protein requirement in different phases of critical illness, in different subgroups, and in nutritionally high-risk patients. [2]此外，仍需要來自精心設計的隨機多中心對照試驗的長期療效和安全性數據，以將 EUS 引導的程序提升到一個新的水平。 [1] 因此，需要精心設計的隨機多中心臨床試驗來評估危重疾病不同階段、不同亞組和營養高危患者的最佳蛋白質需求。 [2]
Controlled Randomized Multicenter 受控隨機多中心
Crizanlizumab was evaluated in a phase 2, double-blind, placebo-controlled randomized multicenter trial comparing high-dose (5 mg/kg) crizanlizumab, low-dose (2. [1] Expert opinion: In two placebo-controlled randomized multicenter phase 2 trials adjunct CNB showed unusually high efficacy with rates of seizure-free people with epilepsy (PWE) partially beyond 20%. [2]crizanlizumab 在一項 2 期、雙盲、安慰劑對照的隨機多中心試驗中進行了評估，該試驗比較了高劑量 (5 mg/kg) crizanlizumab、低劑量 (2. [1] 專家意見：在兩項安慰劑對照的隨機多中心 2 期試驗中，輔助 CNB 顯示出異常高的療效，癲癇患者 (PWE) 的無癲癇發作率部分超過 20%。 [2]
randomized multicenter trial 隨機多中心試驗
This time, we conducted this study to compare the efficacies and complication rates of uncovered MS and covered MS in unresectable malignant distal biliary obstructions at a prospective randomized multicenter trial. [1] Methods This post-hoc analysis from a prospective randomized multicenter trial included 225 patients with a 48-week follow-up period. [2] The study was a randomized multicenter trial using a 2 × 2 diet-by-PA design. [3] Crizanlizumab was evaluated in a phase 2, double-blind, placebo-controlled randomized multicenter trial comparing high-dose (5 mg/kg) crizanlizumab, low-dose (2. [4] This 12-week randomized multicenter trial evaluated efficacy and safety of TNX-102 SL, a bedtime sublingual formulation of cyclobenzaprine, in patients with military-related PTSD randomized to TNX-102 SL 2. [5] The limitations of ANT DBS studies include a limited number of patients treated and mostly open-label designs with only one double-blind, randomized multicenter trial. [6] Methods This single-blinded randomized multicenter trial at four tertiary hospitals from June 2019 to June 2020 included patients aged 19 to 85 years undergoing ESD. [7] However, further evaluation in a larger randomized multicenter trial is warranted. [8] This is the description of a phase IIb randomized multicenter trial that involves the enrolment of 96 patients. [9] To date, there is a lack of robust published data regarding the safety and effectiveness of various therapies, and there continues to be a need for large randomized multicenter trials comparing newer therapies to treat this refractory condition. [10] STUDY DESIGN Post-hoc analysis of 5-year follow-up data from a prospective randomized multicenter trial. [11] Large prospective randomized multicenter trials are needed to refine the cut-off values and algorithms and validate the clinical usefulness of these biomarkers. [12] Randomized multicenter trials have shown that a combined end- point consisting of death, myocardial infarction, or revascularization arose signifi- cantly less commonly in the FFR group than in the group receiving angiography without FFR (13. [13] Methods This is a secondary analysis of the randomized multicenter trial PROSPERE, which compared morbidity after prolapse repair with mesh according to the vaginal or laparoscopic approach. [14] Materials and Methods: The study program included two 12-month, prospective, controlled, cluster-randomized multicenter trials. [15] Methods In a randomized multicenter trial conducted on patients with new-onset MRSA infection we evaluated the efficacy of an early eradication treatment (arm A) compared with an observational group (B). [16] Methods TAPPAS was a randomized multicenter trial of TRC105/P vs P that enrolled cutaneous and non-cutaneous AS patients and incorporated an adaptive enrichment design. [17] A large, randomized multicenter trial uncovered this hope as a deadly illusion and established that the antiarrhythmic therapy in fact increased arrhythmic mortality and caused premature death in thousands of patients. [18] The PEPuP protocol results in 12–15% increase in the amount of protein and calories received by the patient in the context of a cluster randomized multicenter trial [8]. [19] The REVERT trial was a randomized multicenter trial that investigated the efficacy of using a modified Valsalva maneuver for the reversion of stable supraventricular tachycardia back to a sinus rhythm. [20] Further evidence can be expected from ongoing randomized multicenter trials. [21] Design, Setting, and Participants Patient data from 7 randomized multicenter trials were pooled. [22] The authors tested the effectiveness of a work‐related medical rehabilitation program compared with conventional medical rehabilitation using a cluster‐randomized multicenter trial (German Clinical Trial Register: DRKS00007770). [23] However, further long-term prospective randomized multicenter trials involving comparative studies are necessary to confirm these findings. [24] This prospective randomized multicenter trial comparing in utero fetal MMC (fMMC) closure to routine postnatal closure demonstrated a decreased need for shunting, reversal of hindbrain herniation, and improved neurologic function in the prenatal repair group, although maternal complications and prematurity were more frequently encountered. [25] The efficacy and safety of tafluprost, as well as that of tafluprost/timolol fixed combination (FC), was demonstrated in randomized multicenter trials. [26] We hypothesized that abnormalities on EEG would also be associated with cognitive outcome in patients with moderate-to-severe TBI in a post-hoc analysis of a prospective, randomized multicenter trial. [27] Radiotherapy of painful heel spur with two fractionation regimens : Results of a randomized multicenter trial after 48 weeks’ follow-up. [28] Nevertheless, several recent randomized multicenter trials provide new insights into renal replacement strategies, composition of intravenous fluid replacement, goal-directed fluid therapy, or remote ischemic preconditioning in their impact on perioperative acute kidney injury. [29] In this prospective nonrandomized multicenter trial, we analyze the incidence of early and late complications after parotidectomy in correlation to the extent of dissection. [30] Early phase I and II studies have shown the benefits of PRRT, but it was the NETTER-1 trial (a large-scale randomized multicenter trial for progressive well-differentiated advanced or metastatic somatostatin receptor-positive midgut carcinoid tumors) that provided high-level evidence of improved overall response rate, and progression-free survival compared with long-acting octreotide. [31] Methods: In this randomized multicenter trial, patients with symptomatic lumbar disc herniation and with a large annular defect following limited lumbar discectomy were randomized to bone-anchored ACD or Control groups. [32] Design, Setting, and Participants In this randomized multicenter trial with 3-month follow-up, patients were assigned week-wise to one of the pathways between June 15, 2015, and November 15, 2017, in 2 regions of Saarland, Germany; 708 of 824 suspected stroke patients did not meet inclusion criteria, resulting in a study population of 116 adult patients. [33] The efficacy and safety of tafluprost, as well as tafluprost/timolol fixed combination (FC), were demonstrated in randomized multicenter trials. [34] A recently begun randomized multicenter trial of surgical interventions will provide insight into the indications for surgical intervention, optimal timing and choice of intervention, and long-term outcomes. [35]這一次，我們進行了這項研究，以在一項前瞻性隨機多中心試驗中比較未覆蓋 MS 和覆蓋 MS 在不可切除的惡性遠端膽道梗阻中的療效和並發症發生率。 [1] 方法 這項來自前瞻性隨機多中心試驗的事後分析包括 225 名患者，隨訪期為 48 週。 [2] 該研究是一項隨機多中心試驗，採用 2 × 2 飲食-PA 設計。 [3] crizanlizumab 在一項 2 期、雙盲、安慰劑對照的隨機多中心試驗中進行了評估，該試驗比較了高劑量 (5 mg/kg) crizanlizumab、低劑量 (2. [4] 這項為期 12 週的隨機多中心試驗評估了 TNX-102 SL（一種環苯扎林的睡前舌下製劑）在隨機分配至 TNX-102 SL 2 的軍事相關 PTSD 患者中的療效和安全性。 [5] ANT DBS 研究的局限性包括接受治療的患者數量有限，並且大多是開放標籤設計，只有一項雙盲、隨機多中心試驗。 [6] 方法 這項於 2019 年 6 月至 2020 年 6 月在四家三級醫院開展的單盲隨機多中心試驗納入了 19 至 85 歲接受 ESD 的患者。 [7] 然而，需要在更大的隨機多中心試驗中進行進一步評估。 [8] 這是一項涉及 96 名患者登記的 IIb 期隨機多中心試驗的描述。 [9] 迄今為止，缺乏關於各種療法的安全性和有效性的可靠已發表數據，並且仍然需要大型隨機多中心試驗來比較治療這種難治性疾病的新療法。 [10] 學習規劃 一項前瞻性隨機多中心試驗的 5 年隨訪數據的事後分析。 [11] 需要大型前瞻性隨機多中心試驗來完善臨界值和算法，並驗證這些生物標誌物的臨床實用性。 [12] 隨機多中心試驗表明，由死亡、心肌梗死或血運重建組成的綜合終點在 FFR 組中的發生率顯著低於接受血管造影但沒有 FFR 的組（13. [13] 方法 這是對隨機多中心試驗 PROSPERE 的二次分析，該試驗比較了根據陰道或腹腔鏡方法使用網片修復脫垂後的發病率。 [14] 材料和方法：研究計劃包括兩項為期 12 個月的前瞻性、對照、整群隨機多中心試驗。 [15] 方法 在對新發 MRSA 感染患者進行的一項隨機多中心試驗中，我們評估了早期根除治療（A 組）與觀察組（B）相比的療效。 [16] 方法 TAPPAS 是一項 TRC105/P 與 P 的隨機多中心試驗，納入皮膚和非皮膚 AS 患者，並採用適應性富集設計。 [17] 一項大型隨機多中心試驗發現這種希望是一種致命的幻覺，並確定抗心律失常治療實際上增加了心律失常死亡率並導致數千名患者過早死亡。 [18] 在一項集群隨機多中心試驗的背景下，PEPuP 方案導致患者攝入的蛋白質和卡路里量增加 12-15% [8]。 [19] REVERT 試驗是一項隨機多中心試驗，研究使用改良的 Valsalva 動作將穩定的室上性心動過速恢復為竇性心律的效果。 [20] 可以從正在進行的隨機多中心試驗中獲得更多證據。 [21] 設計、設置和參與者 來自 7 個隨機多中心試驗的患者數據被匯總。 [22] 作者使用集群隨機多中心試驗（德國臨床試驗註冊：DRKS00007770）測試了與工作相關的醫療康復計劃與傳統醫療康復相比的有效性。 [23] 然而，需要進一步的涉及比較研究的長期前瞻性隨機多中心試驗來證實這些發現。 [24] 這項前瞻性隨機多中心試驗比較了子宮內胎兒 MMC (fMMC) 閉合與常規產後閉合的比較，表明產前修復組的分流需求減少、後腦疝逆轉和神經功能改善，儘管母體並發症和早產的發生率更高。 [25] 隨機多中心試驗證明了他氟前列素以及他氟前列素/噻嗎洛爾固定組合 (FC) 的有效性和安全性。 [26] 在一項前瞻性、隨機多中心試驗的事後分析中，我們假設腦電圖異常也與中重度 TBI 患者的認知結果相關。 [27] 兩種分割方案對疼痛性足跟骨刺的放射治療：48 週隨訪後的隨機多中心試驗結果。 [28] 然而，最近的幾項隨機多中心試驗為腎臟替代策略、靜脈補液的組成、目標導向的液體治療或遠程缺血預處理對圍手術期急性腎損傷的影響提供了新的見解。 [29] 在這項前瞻性非隨機多中心試驗中，我們分析了腮腺切除術後早期和晚期並發症的發生率與解剖範圍的相關性。 [30] 早期 I 期和 II 期研究顯示了 PRRT 的益處，但 NETTER-1 試驗（一項針對進行性高分化晚期或轉移性生長抑素受體陽性中腸類癌的大規模隨機多中心試驗）提供了高水平與長效奧曲肽相比，總體緩解率和無進展生存期得到改善的證據。 [31] nan [32] nan [33] nan [34] nan [35]
randomized multicenter study 隨機多中心研究
Methods: This is a double-blind randomized multicenter study in 36 centers in the U. [1] Several randomized multicenter studies have identified intraocular pressure as the major risk factor for its development, caused by an increased outflow resistance to the aqueous humor within the trabecular meshwork. [2] In case the results indicate that cognitive performance can be improved with CR, and whether or not tDCS will lead to additional improvement, this pilot trial will be extended to a large randomized multicenter study. [3] It should be pointed out that the scientific literature is to some extent controversial due to a paucity of large randomized multicenter studies with long-term follow-up. [4] Materials and methods: a retrospective uncontrolled non-randomized multicenter study of 821 women and 836 children under the age of 3 years. [5] Methods The CILOVE study was a phase II prospective non-randomized multicenter study. [6] We conducted this study to explore the role of the molecular tumor burden index (mTBI) in ctDNA as a therapeutic response and prognostic biomarker in a larger cohort prospective phase III randomized multicenter study. [7] Further evaluation through randomized multicenter studies focusing on the different subgroups and comorbidities in larger populations and correlation with appropriate treatment options is necessary. [8] Larger, prospective randomized multicenter studies are needed in order to confirm these findings. [9] These results need to be confirmed in randomized multicenter studies. [10] A prospective randomized multicenter study (Envision) demonstrated the clinical efficacy of monthly subcutaneous injection of Givosiran for the prevention of attacks of acute hepatic porphyria (AHP). [11] To explore the risk of encrustation and biofilm formation for silicone ureteral stents compared to percuflex polymer stents, through a randomized multicenter study. [12] Materials and Methods: Nationwide prospective randomized multicenter study involving 43 centers throughout France allowing for the inclusion of >70% of all French cardiology residents. [13] Interestingly, a well-designed prospective randomized multicenter study (PIONEER-HF) showed an improved clinical outcome and stress/injury biomarker profile after in-hospital administration of sacubitril/valsartan (sac/val) as compared to enalapril, in hemodynamically stable patients with AHF. [14] Two prospective randomized multicenter studies (PIONEER-HF and TRANSITION) in patients hospitalized for acute heart failure (AHF) have shown an improved clinical outcome and biomarker profile as compared to enalapril, and good tolerability, safety and feasibility of initiating in-hospital administration of S/V. [15] Methods A prospective randomized multicenter study was performed. [16] METHODS Patients with inoperable high-grade MHSs were enrolled in this prospective randomized multicenter study. [17] Management is based on observational data, while randomized multicenter studies are still lacking. [18] Background This study aimed to compare the functional and clinical outcomes between the deltoid split (DS) approach and the classic deltopectoral (DP) approach for locking plate fixation of proximal humerus fractures (PHF) in a prospective randomized multicenter study. [19] In a pre‐specified subgroup analysis of a 12‐week randomized multicenter study, we investigated effects of valsartan/amlodipine 80/5 mg single‐pill combination (n = 75) and nifedipine GITS 30 mg (n = 75) on ambulatory blood pressure (BP) and arterial stiffness assessed by brachial‐ankle pulse wave velocity (PWV) in patients with uncontrolled hypertension. [20] METHODS This prospective nonrandomized multicenter study analyzed patients treated for carotid artery stenosis with CAS from January 2014 to August 2016. [21] Further large randomized multicenter studies are required to find influence of obesity in relation to ethnicity and other factors to ovarian reserve function. [22] Methods From 2015 to 2017 a randomized multicenter study was conducted. [23] Since encrustation remains a significant concern when stents are implanted, we investigated these properties of silicone through a randomized multicenter study. [24] Methods— Patients with acute cerebral ischemia ≥60 years presenting in sinus rhythm and without history of AF were included into a prospective, randomized multicenter study to receive either EPM (3× 10-day Holter-ECG) or usual stroke care diagnostic work-up. [25] The GEINO-14-01 trial (NCT02209948) investigated the role of extending adjuvant TMZ to 12 cycles in a randomized multicenter study. [26] Methods: The HEMO study was a randomized multicenter study evaluating the effects of high-dose vs. [27] DESIGN This prospective randomized multicenter study determined whole-body and liver protein synthesis, splanchnic protein metabolism and appendicular skeletal muscle mass (ASMM) in 24 malnourished older patients [80-92 years; 18 women and 6 men] in inpatient rehabilitation units. [28] A large randomized multicenter study highlighted doxycycline as a feasible alternative to systemic corticosteroids in patients not suitable for long-term steroid use. [29]方法：這是一項在美國 36 個中心進行的雙盲隨機多中心研究。 [1] 幾項隨機多中心研究已確定眼壓是其發展的主要危險因素，這是由於小梁網內房水流出阻力增加所致。 [2] 如果結果表明 CR 可以改善認知能力，以及 tDCS 是否會帶來額外的改善，該試點試驗將擴展到一項大型隨機多中心研究。 [3] 應該指出的是，由於缺乏長期隨訪的大型隨機多中心研究，科學文獻在一定程度上存在爭議。 [4] 材料和方法：一項對 821 名婦女和 836 名 3 歲以下兒童的回顧性非對照非隨機多中心研究。 [5] 方法 CILOVE 研究是一項 II 期前瞻性非隨機多中心研究。 [6] 我們進行了這項研究，以探索分子腫瘤負荷指數 (mTBI) 在 ctDNA 中作為治療反應和預後生物標誌物在更大的隊列前瞻性 III 期隨機多中心研究中的作用。 [7] 有必要通過隨機多中心研究進一步評估，重點關注更大人群中的不同亞組和合併症以及與適當治療方案的相關性。 [8] 需要更大規模的前瞻性隨機多中心研究來證實這些發現。 [9] 這些結果需要在隨機多中心研究中得到證實。 [10] 一項前瞻性隨機多中心研究 (Envision) 證明了每月皮下注射 Givosiran 對預防急性肝卟啉症 (AHP) 發作的臨床療效。 [11] 通過一項隨機多中心研究，探討與 percuflex 聚合物支架相比，矽膠輸尿管支架結痂和生物膜形成的風險。 [12] 材料和方法：全國性前瞻性隨機多中心研究，涉及全法國 43 個中心，納入了超過 70% 的法國心髒病學住院醫師。 [13] 有趣的是，一項精心設計的前瞻性隨機多中心研究 (PIONEER-HF) 顯示，與依那普利相比，在院內給予沙庫巴曲/纈沙坦 (sac/val) 後，在血流動力學穩定的患有心力衰竭。 [14] 兩項針對急性心力衰竭 (AHF) 住院患者的前瞻性隨機多中心研究（PIONEER-HF 和 TRANSITION）顯示，與依那普利相比，臨床結果和生物標誌物譜有所改善，並且在院內開始使用本品具有良好的耐受性、安全性和可行性。 S/V。 [15] 方法進行前瞻性隨機多中心研究。 [16] 方法 這項前瞻性隨機多中心研究招募了不能手術的高級 MHS 患者。 [17] 管理基於觀察數據，而隨機多中心研究仍然缺乏。 [18] 背景 本研究旨在在一項前瞻性隨機多中心研究中比較三角肌劈開 (DS) 入路與經典三角胸肌 (DP) 入路鎖定鋼板固定肱骨近端骨折 (PHF) 的功能和臨床結果。 [19] 在一項為期 12 週的隨機多中心研究的預先指定的亞組分析中，我們調查了纈沙坦/氨氯地平 80/5 mg 單丸組合 (n = 75) 和硝苯地平 GITS 30 mg (n = 75) 對動態血壓的影響通過臂踝脈搏波速度 (PWV) 評估未控制的高血壓患者的 (BP) 和動脈僵硬度。 [20] 方法 這項前瞻性非隨機多中心研究分析了 2014 年 1 月至 2016 年 8 月接受 CAS 治療的頸動脈狹窄患者。 [21] 需要進一步的大型隨機多中心研究來發現肥胖與種族和其他因素對卵巢儲備功能的影響。 [22] 方法 從 2015 年到 2017 年，進行了一項隨機多中心研究。 [23] 由於植入支架時結殼仍然是一個重要問題，我們通過一項隨機多中心研究調查了矽膠的這些特性。 [24] 方法——將患有竇性心律且無 AF 病史的 60 歲以上急性腦缺血患者納入一項前瞻性隨機多中心研究，接受 EPM（3×10 天 Holter-ECG）或常規卒中護理診斷檢查. [25] GEINO-14-01 試驗 (NCT02209948) 在一項隨機多中心研究中調查了將輔助 TMZ 延長至 12 個週期的作用。 [26] nan [27] nan [28] 一項大型隨機多中心研究強調，對於不適合長期使用類固醇的患者，強力黴素是全身性皮質類固醇的可行替代品。 [29]
randomized multicenter clinical 隨機多中心臨床
Objective: We aimed to evaluate the efficacy and safety of endobronchial coil treatment in a randomized multicenter clinical trial using optimized patient selection. [1] If the improvement occurs, we plan to design a randomized multicenter clinical trial to confirm the findings. [2] Large randomized multicenter clinical trials are needed to discern the exact therapeutic potentials of MSC in COVID-19-induced ARDS. [3] If the improvement occurs, we plan to design a randomized multicenter clinical trial to confirm the findings. [4] DESIGN AND SAMPLE Randomized multicenter clinical trial with 522 mothers of children under 5 years of age from northeastern Brazil. [5] DESIGN, SETTING, AND PARTICIPANTS We performed germline panel sequencing for 201 men with intermediate- and high-risk localized PCa from five randomized multicenter clinical trials of intense neoadjuvant ADT before RP. [6] The objective of the study: the evaluation of the effectiveness and toxicity of R-DA-EPOCH and R-mNHL-BFM-90 induction courses in DLBCL patients with poor prognostic factors in a randomized multicenter clinical trial “DLBCL-2015”. [7] Methods In a prospective randomized multicenter clinical trial, patients with solid pancreatic lesions underwent EUS-FNB with either a 20-gauge or a 25-gauge FNB needle. [8] Despite current data supporting 125I seed implantation for some solid carcinomas, there is a need for prospectively-randomized multicenter clinical trials to gather strong evidence for using 125I seed implantation in other solid carcinomas. [9] Therefore, there is a need for a well-designed randomized multicenter clinical trial to evaluate the optimal protein requirement in different phases of critical illness, in different subgroups, and in nutritionally high-risk patients. [10] Design, Setting, and Participants This randomized multicenter clinical trial was conducted at 6 hospitals in the Netherlands, Germany, Italy, Hong Kong, and the United States. [11] Design, Setting, and Participants The IRIS trial was a randomized multicenter clinical trial in patients with prior stroke or transient ischemic attack as well as insulin resistance but not diabetes. [12]目的：我們旨在通過優化患者選擇在一項隨機多中心臨床試驗中評估支氣管內彈簧圈治療的有效性和安全性。 [1] 如果出現改善，我們計劃設計一項隨機多中心臨床試驗來確認研究結果。 [2] 需要大型隨機多中心臨床試驗來辨別 MSC 在 COVID-19 誘導的 ARDS 中的確切治療潛力。 [3] 如果出現改善，我們計劃設計一項隨機多中心臨床試驗來確認研究結果。 [4] 設計和样品 來自巴西東北部的 522 名 5 歲以下兒童母親的隨機多中心臨床試驗。 [5] 設計、設置和參與者 我們對來自 RP 前強新輔助 ADT 的五項隨機多中心臨床試驗的 201 名中危和高危局限性 PCa 男性進行了生殖系面板測序。 [6] 研究目的：在隨機多中心臨床試驗“DLBCL-2015”中評估 R-DA-EPOCH 和 R-mNHL-BFM-90 誘導課程在預後因素較差的 DLBCL 患者中的有效性和毒性。 [7] 方法 在一項前瞻性隨機多中心臨床試驗中，胰腺實性病變患者使用 20 號或 25 號 FNB 針進行 EUS-FNB。 [8] 儘管目前的數據支持 125I 粒子植入治療某些實體癌，但仍需要前瞻性隨機多中心臨床試驗來收集強有力的證據，以將 125I 粒子植入用於其他實體癌。 [9] 因此，需要精心設計的隨機多中心臨床試驗來評估危重疾病不同階段、不同亞組和營養高危患者的最佳蛋白質需求。 [10] 設計、設置和參與者 這項隨機多中心臨床試驗在荷蘭、德國、意大利、香港和美國的 6 家醫院進行。 [11] nan [12]
randomized multicenter phase 隨機多中心階段
Expert opinion: In two placebo-controlled randomized multicenter phase 2 trials adjunct CNB showed unusually high efficacy with rates of seizure-free people with epilepsy (PWE) partially beyond 20%. [1] Purpose What are the patient characteristics predictive of response to ranibizumab treatment? Methods Model-based characterization of best-corrected visual acuity (BCVA) time profiles of patients with neovascular age-related macular degeneration under ranibizumab or sham treatment based on 24-month observations of BCVA in 2419 patients from randomized multicenter phase 3 trials of ranibizumab: ANCHOR, MARINA, PIER, and HARBOR. [2] Five large scale randomized multicenter phase III trials have been conducted to evaluate the efficacy of liraglutide as a weight loss agent. [3] Methods/designThe study is a two arm, open, randomized multicenter Phase III trial with patients over 70 years old with stage IIA-IVB (UICC 2002, IVB only with metastasis to supraclavicular or celiac lymph nodes) squamous cell carcinoma or adenocarcinoma of esophagus or gastroesophageal junction. [4] PURPOSE/OBJECTIVE On September 2009: We started a randomized multicenter phase III study comparing chemoradiation (CRT) (Aldestein RTOG regimen) versus induction chemotherapy followed by Cetuximab radiation (IBRT). [5] We performed a prospective analysis involving the intention-to-treat population of the (Metformin and Trastuzumab in Neoadjuvancy) METTEN study, a randomized multicenter phase II trial of women with primary, non-metastatic (human epidermal growth factor receptor 2) HER2-positive BC evaluating the efficacy, tolerability, and safety of oral metformin (850 mg twice-daily) for 24 weeks combined with anthracycline/taxane-based chemotherapy and trastuzumab (arm A) or equivalent regimen without metformin (arm B), before surgery. [6] Methods TBCRC035 is a 1:1 randomized multicenter phase II study evaluating palbociclib at either 125 or 100 mg in combination with physician choice fulvestrant or tamoxifen. [7] Methods This randomized multicenter phase III trial comprises two cohorts of pts deemed fit (Cohort 1) to receive high dose cisplatin (CDDP 100 mg/m², Q3W) or unfit (Cohort 2) to receive CDDP. [8]專家意見：在兩項安慰劑對照的隨機多中心 2 期試驗中，輔助 CNB 顯示出異常高的療效，癲癇患者 (PWE) 的無癲癇發作率部分超過 20%。 [1] 目的 哪些患者特徵可以預測對雷珠單抗治療的反應？方法 根據雷珠單抗隨機多中心 3 期試驗中 2419 名患者 24 個月的 BCVA 觀察，對接受雷珠單抗或假治療的新生血管性年齡相關性黃斑變性患者的最佳矯正視力 (BCVA) 時間曲線進行基於模型的表徵：錨、碼頭、碼頭和港口。 [2] 已經進行了五項大規模隨機多中心 III 期試驗，以評估利拉魯肽作為減肥藥的功效。 [3] 方法/設計該研究是一項兩臂、開放、隨機多中心 III 期試驗，患者年齡超過 70 歲，IIA-IVB 期（UICC 2002，IVB 僅轉移至鎖骨上或腹腔淋巴結）鱗狀細胞癌或食管腺癌或胃食管交界處。 [4] 目的/目標 2009 年 9 月：我們開始一項隨機多中心 III 期研究，比較放化療 (CRT)（Aldestein RTOG 方案）與誘導化療後西妥昔單抗放療 (IBRT)。 [5] 我們進行了一項前瞻性分析，涉及意向治療人群（二甲雙胍和曲妥珠單抗在 Neoadjuvancy）METTEN 研究，這是一項針對原發性非轉移性（人表皮生長因子受體 2）HER2 陽性女性的隨機多中心 II 期試驗BC 在手術前評估口服二甲雙胍（850 mg，每天兩次）聯合基於蒽環類/紫杉烷的化療和曲妥珠單抗（A 組）或不含二甲雙胍的等效方案（B 組）的療效、耐受性和安全性 24 週。 [6] nan [7] nan [8]
randomized multicenter controlled 隨機多中心控制
Moreover, data on long-term efficacy and safety coming from well-designed randomized multicenter controlled trials are still needed to bring EUS-guided procedures to the next level. [1] This is a Commentary on "Enhanced Enteral Feeding Versus Traditional Feeding in Neonatal Congenital Gastrointestinal Malformation Undergoing Intestinal Anastomosis: A Randomized Multicenter Controlled Trial of an Enhanced Recovery After Surgery (ERAS) Component" by Peng Y, Xiao D, Xiao S, et al. [2] The review highlights the analysis of modern literature data from randomized multicenter controlled trials conducted in the world in order to determine the optimal strategy for perioperative fluid therapy in both planned and urgent interventions. [3] BACKGROUND To our knowledge, there is an absence of prospective randomized multicenter controlled trials evaluating both the impact of technique and mesh type on outcomes in complicated ventral hernia repair. [4]此外，仍需要來自精心設計的隨機多中心對照試驗的長期療效和安全性數據，以將 EUS 引導的程序提升到一個新的水平。 [1] 這是對“強化腸內餵養與傳統餵養在接受腸吻合術的新生兒先天性胃腸道畸形中的對比：加速術後恢復 (ERAS) 組件的隨機多中心對照試驗”的評論，作者 Peng Y、Xiao D、Xiao S 等。 [2] 該綜述重點分析了世界範圍內進行的隨機多中心對照試驗的現代文獻數據，以確定計劃和緊急干預措施中圍手術期液體治療的最佳策略。 [3] 背景 據我們所知，目前尚無前瞻性隨機多中心對照試驗評估技術和補片類型對複雜腹疝修復結果的影響。 [4]
randomized multicenter prospective 隨機多中心前瞻性
There is a need for a large-scale randomized multicenter prospective study to verify the advantages of minimally invasive approaches in the management of symptomatic supratentorial intracerebral hemorrhages. [1] We intend to continue to report program outcomes and have planned new randomized multicenter prospective studies. [2] This randomized multicenter prospective BEGIN trial compared the biodegradable polymer-based biolimus A9-eluting stent (2-link BES) with the durable polymer-based cobalt chromium everolimus-eluting stent (3-link EES) in 226 patients with de novo CBLs. [3] Patients and methods This is a randomized multicenter prospective study with 12 weeks of follow-up. [4]需要一項大規模隨機多中心前瞻性研究來驗證微創方法在治療症狀性幕上腦出血中的優勢。 [1] 我們打算繼續報告項目結果，併計劃進行新的隨機多中心前瞻性研究。 [2] 這項隨機多中心前瞻性 BEGIN 試驗在 226 名新發 CBL 患者中比較了基於生物可降解聚合物的 biolimus A9 洗脫支架（2-link BES）與耐用的基於聚合物的鈷鉻依維莫司洗脫支架（3-link EES）。 [3] 患者和方法 這是一項為期 12 週的隨機多中心前瞻性研究。 [4]